It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
What impact would it have on your AAV manufacturing if you were able to match your cell line with your program goals? This webinar will highlight how the use of advanced cell lines can empower researchers and developers to realize the full potential of gene therapy.
Insights will be presented on a comprehensive portfolio of cell lines engineered to transform AAV manufacturing. The strategic development behind these innovative cell lines, designed to provide tailored solutions for diverse gene therapy needs, will be explored. The benefits of the portfolio for producing therapeutic AAVs will also be outlined - from enhancing productivity and scalability to ensuring high-quality viral vectors.
- Discover the differences between transient, packaging, and producer cell lines for producing AAV
- Explore how the range of options provides the opportunity to tailor the choice for each therapeutic program and seamlessly transition from R&D through manufacturing as needs evolve
- Uncover how cell line engineering can tackle host cell DNA (hcDNA) including hcDNA inside capsids, a contaminant that can’t be removed in current downstream processing
SPEAKERS
You might also like
Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering
Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness
Advancing viral vector manufacturing with innovation: the importance of the cell line
